QIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN, today announced the launch of their new cell line database developed through its partnership with ATCC, the leading biological materials organization, developer and supplier of authenticated cell lines.
An externally facilitated clinical NGS interpretation validation study published in the Journal of Molecular Pathology demonstrates how QCI Interpret One achieves a higher level of concordance with a panel of experts than human reviewers achieve amongst each other.
QIAGEN announced that its decision-support software platform QIAGEN Clinical Insights (QCI) has been used to interpret more than three million patient molecular profiles for hereditary and oncological diseases to date.
QIAGEN gives drug research direct access to world-leading data with launch of QIAGEN Biomedical Knowledge Base, supporting data science applications in pharmaceuticals and biotechnology that are becoming ever more important for drug discovery.
NHS England and NHS Improvement will use QIAGEN’s HGMD Online Professional to support scientists and clinician across its network of 7 NHS Laboratory Hubs with clinical reporting and interpretation of genomic data.
QIAGEN today announced the launch of the QIAGEN Digital Insights Partnership program for genomic vendors to leverage QIAGEN’s genomic content and analysis leadership to expand customer access and deliver extended genomic solutions for scientists and clinicians.
